| Version |
2.5 |
| Creation Date |
2005-06-13 13:24:05 |
| Update Date |
2009-02-19 16:04:42 |
| Primary Accession Number |
DB00426 |
| Secondary Accession Number |
|
| Name |
Famciclovir |
| Drug Type |
|
| Description |
Famciclovir is a guanine analogue antiviral drug used for the treatment of various herpes virus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis). |
| Synonyms |
- FCV
- Famciclovirum [INN-Latin]
|
| Brand Names |
- Famvir
|
| Brand Mixtures |
Not Available |
| Chemical IUPAC Name |
[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate |
| Chemical Formula |
C14H19N5O4 |
| Chemical Structure |
 |
| CAS Registry Number |
104227-87-4 |
| InChI Identifier |
InChI=1/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)/f/h15H2 |
| InChI Key |
GGXKWVWZWMLJEH-YHSKDTNECV |
| KEGG Drug |
D00317  |
| KEGG Compound |
Not Available |
| PubChem Compound |
3324  |
| PubChem Substance |
196284  |
| ChEBI ID |
Not Available |
| PharmGKB ID |
PA449585  |
| HET ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
02229110  |
| RxList Link |
http://www.rxlist.com/cgi/generic3/famciclovir.htm  |
| PDRhealth Link |
Not Available |
| Wikipedia Link |
http://en.wikipedia.org/wiki/Famciclovir  |
| FDA Label |
|
| Material Safety Data Sheet (MSDS) |
Not Available |
| Synthesis Reference |
Geen, et al.; Tetrahedron Lett.; 33; 32;4609-4612(1992). |
| Average Molecular Weight |
321.3318 |
| Monoisotopic Molecular Weight |
321.1437 |
| State |
Solid |
| Melting Point |
102-104 oC |
| Experimental Water Solubility |
Not Available
Source: PhysProp
|
| Predicted Water Solubility |
1.32e+00 mg/mL
Calculated using ALOGPS
|
| Experimental LogP/Hydrophobicity |
0.6
Source: PhysProp
|
| Predicted LogP |
0.14
Calculated using ALOGPS
|
| Experimental LogS |
Not Available |
| Predicted LogS |
-2.39
Calculated using ALOGPS
|
| Experimental Caco2 Permeability |
Not Available |
| pKa/Isoelectric Point |
Not Available |
| Mass Spectrum |
Not Available
|
| MOL File |
Show | Download  |
| SDF File |
Show | Download  |
| PDB File |
Show | Download  |
| 2D Structure |
|
| 3D Structure |
|
| Experimental PDB ID |
Not Available |
| Isomeric SMILES |
CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O |
| Canonical SMILES |
CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O |
| Drug Category |
- Antiviral Agents
- Nucleosides and Nucleotides
- Prodrugs
|
| ATC Codes |
|
| AHFS Codes |
|
| Indication |
For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients. |
| Pharmacology |
Famciclovir is a prodrug that undergoes rapid biotransformation to the active antiviral compound penciclovir. Penciclovir is an anti-viral drug which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). Therefore, herpes viral DNA synthesis and replication are selectively inhibited. |
| Mechanism of Action |
Famciclovir undergoes rapid biotransformation to the active antiviral compound penciclovir, which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). In cells infected with HSV-1, HSV-2 or VZV, viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted to penciclovir triphosphate by cellular kinases. In vitro studies demonstrate that penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. |
| Absorption |
77 % |
| Toxicity |
Symptoms of overdose include constipation, diarrhea, dizziness, fatigue, fever, headache, nausea, and vomiting. |
| Protein Binding |
20-25% |
| Biotransformation |
Hepatic |
| Half Life |
10 hours |
| Dosage Forms |
|
| Patient Information |
Show  |
| Contraindications |
Show  |
| Interactions |
Show  |
| Drug Interactions |
Not Available
|
| Food Interactions |
- Take without regard to meals.
|
| Pathways |
Not Available
|
| General References |
- Wikipedia

- RxList

|
| Organisms Affected |
|
| Phase 1 Metabolizing Enzymes |
- Aldehyde oxidase
|
| Targets |
- DNA polymerase
- DNA polymerase
|
|
Drug Target 1
[top]
|
| Target 1 ID |
338 |
| Target 1 Name |
DNA polymerase |
| Target 1 Synonyms |
- EC 2.7.7.7
|
| Target 1 Gene Name |
UL30 |
| Target 1 Protein Sequence |
>DNA polymerase
MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTG
PTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSG
GFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGT
VITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASF
RGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDAT
TRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLP
AYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLP
ESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLT
DIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKL
NAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSA
VARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAARED
EERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFAS
LYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRD
WLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTI
GREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAA
GLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRK
NNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRR
ITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQT
REVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVS
ELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPD
DVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA
|
| Target 1 Number of Residues |
1255 |
| Target 1 Molecular Weight |
136422 |
| Target 1 Theoretical pI |
7.31 |
| Target 1 GO Classification |
|
Function
|
hydrolase activity
hydrolase activity, acting on ester bonds
nuclease activity
exonuclease activity
3'-5' exonuclease activity
catalytic activity
transferase activity
transferase activity, transferring phosphorus-containing groups
nucleotidyltransferase activity
DNA-directed DNA polymerase activity
nucleic acid binding
DNA binding
binding
nucleotide binding |
|
Process
|
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
DNA metabolism
DNA replication |
|
Component
|
| Not Available |
|
| Target 1 General Function |
Replication, recombination and repair |
| Target 1 Specific Function |
Not Available |
| Target 1 Pathways |
|
| Target 1 Reactions |
- deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1
|
| Target 1 Pfam Domain Function |
|
| Target 1 Signals |
|
| Target 1 Transmembrane Regions |
|
| Target 1 Essentiality |
Non-Essential |
| Target 1 GenBank ID Protein |
59530  |
| Target 1 UniProtKB/Swiss-Prot ID |
P04293  |
| Target 1 UniProtKB/Swiss-Prot Entry Name |
DPOL_HHV11  |
| Target 1 PDB ID |
Not Available |
| Target 1 Cellular Location |
|
| Target 1 Gene Sequence |
>3708 bp
ATGTTTTCCGGTGGCGGCGGCCCGCTGTCCCCCGGAGGAAAGTCGGCGGCCAGGGCGGCG
TCCGGGTTTTTTGCGCCCGCCGGCCCTCGCGGAGCCAGCCGGGGACCCCCGCCTTGTTTG
AGGCAAAACTTTTACAACCCCTACCTCGCCCCAGTCGGGACGCAACAGAAGCCGACCGGG
CCAACCCAGCGCCATACGTACTATAGCGAATGCGATGAATTTCGATTCATCGCCCCGCGG
GTGCTGGACGAGGATGCCCCCCCGGAGAAGCGCGCCGGGGTGCACGACGGTCACCTCAAG
CGCGCCCCCAAGGTGTACTGCGGGGGGGACGAGCGCGACGTCCTCCGCGTCGGGTCGGGC
GGCTTCTGGCCGCGGCGCTCGCGCCTGTGGGGCGGCGTGGACCACGCCCCGGCGGGGTTC
AACCCCACCGTCACCGTCTTTCACGTGTACGACATCCTGGAGAACGTGGAGCACGCGTAC
GGCATGCGCGCGGCCCAGTTCCACGCGCGGTTTATGGACGCCATCACACCGACGGGGACC
GTCATCACGCTCCTGGGCCTGACTCCGGAAGGCCACCGGGTGGCCGTTCACGTTTACGGC
ACGCGGCAGTACTTTTACATGAACAAGGAGGAGGTCGACAGGCACCTACAATGCCGCGCC
CCACGAGATCTCTGCGAGCGCATGGCCGCGGCCCTGCGCGAGTCCCCGGGCGCGTCGTTC
CGCGGCATCTCCGCGGACCACTTCGAGGCGGAGGTGGTGGAGCGCACCGACGTGTACTAC
TACGAGACGCGCCCCGCTCTGTTTTACCGCGTCTACGTCCGAAGCGGGCGTGTGCTGTCG
TACCTGTGCGACAACTTCTGCCCGGCCATCAAGAAGTACGAGGGTGGGGTCGACGCCACC
ACCCGGTTCATCCTGGACAACCCCGGGTTCGTCACCTTCGGCTGGTACCGTCTCAAACCG
GGCCGGAACAACACGCTAGCCCAGCCGGCGGCCCCGATGGCCTTCGGGACATCCAGCGAC
GTCGAGTTTAACTGTACGGCGGACAACCTGGCCATCGAGGGGGGCATGAGCGACCTACCG
GCATACAAGCTCATGTGCTTCGATATCGAATGCAAGGCGGGGGGGGAGGACGAGCTGGCC
TTTCCGGTGGCCGGGCACCCGGAGGACCTGGTCATCCAGATATCCTGTCTGCTCTACGAC
CTGTCCACCACCGCCCTGGAGCACGTCCTCCTGTTTTCGCTCGGTTCCTGCGACCTCCCC
GAATCCCACCTGAACGAGCTGGCGGCCAGGGGCCTGCCCACGCCCGTGGTTCTGGAATTC
GACAGCGAATTCGAGATGCTGTTGGCCTTCATGACCCTTGTGAAACAGTACGGCCCCGAG
TTCGTGACCGGGTACAACATCATCAACTTCGACTGGCCCTTCTTGCTGGCCAAGCTGACG
GACATTTACAAGGTCCCCCTGGACGGGTACGGCCGCATGAACGGCCGGGGCGTGTTTCGC
GTGTGGGACATAGGCCAGAGCCACTTCCAGAAGCGCAGCAAGATAAAGGTGAACGGCATG
GTGAACATCGACATGTACGGGATTATAACCGACAAGATCAAGCTCTCGAGCTACAAGCTC
AACGCCGTGGCCGAAGCCGTCCTGAAGGACAAGAAGAAGGACCTGAGCTATCGCGACATC
CCCGCCTACTACGCCGCCGGGCCCGCGCAACGCGGGGTGATCGGCGAGTACTGCATACAG
GATTCCCTGCTGGTGGGCCAGCTGTTTTTTAAGTTTTTGCCCCATCTGGAGCTCTCGGCC
GTCGCGCGCTTGGCGGGTATTAACATCACCCGCACCATCTACGACGGCCAGCAGATCCGC
GTCTTTACGTGCCTGCTGCGCCTGGCCGACCAGAAGGGCTTTATTCTGCCGGACACCCAG
GGGCGATTTAGGGGCGCCGGGGGGGAGGCGCCCAAGCGTCCGGCCGCAGCCCGGGAGGAC
GAGGAGCGGCCAGAGGAGGAGGGGGAGGACGAGGACGAACGCGAGGAGGGCGGGGGCGAG
CGGGAGCCGGAGGGCGCGCGGGAGACCGCCGGCAGGCACGTGGGGTACCAGGGGGCCAGG
GTCCTTGACCCCACTTCCGGGTTTCACGTGAACCCCGTGGTGGTGTTCGACTTTGCCAGC
CTGTACCCCAGCATCATCCAGGCCCACAACCTGTGCTTCAGCACGCTCTCCCTGAGGGCC
GACGCAGTGGCGCACCTGGAGGCGGGCAAGGACTACCTGGAGATCGAGGTGGGGGGGCGA
CGGCTGTTCTTCGTCAAGGCTCACGTGCGAGAGAGCCTCCTCAGCATCCTCCTGCGGGAC
TGGCTCGCCATGCGAAAGCAGATCCGCTCGCGGATTCCCCAGAGCAGCCCCGAGGAGGCC
GTGCTCCTGGACAAGCAGCAGGCCGCCATCAAGGTCGTGTGTAACTCGGTGTACGGGTTC
ACGGGAGTGCAGCACGGACTCCTGCCGTGCCTGCACGTTGCCGCGACGGTGACGACCATC
GGCCGCGAGATGCTGCTCGCGACCCGCGAGTACGTCCACGCGCGCTGGGCGGCCTTCGAA
CAGCTCCTGGCCGATTTCCCGGAGGCGGCCGACATGCGCGCCCCCGGGCCCTATTCCATG
CGCATCATCTACGGGGACACGGACTCCATCTTTGTGCTGTGCCGCGGCCTCACGGCCGCC
GGGCTGACGGCCGTGGGCGACAAGATGGCGAGCCACATCTCGCGCGCGCTGTTTCTGCCC
CCCATCAAACTCGAGTGCGAAAAGACGTTCACCAAGCTGCTGCTGATCGCCAAGAAAAAG
TACATCGGCGTCATCTACGGGGGTAAGATGCTCATCAAGGGCGTGGATCTGGTGCGCAAA
AACAACTGCGCGTTTATCAACCGCACCTCCAGGGCCCTGGTCGACCTGCTGTTTTACGAC
GATACCGTCTCCGGAGCGGCCGCCGCGTTAGCCGAGCGCCCCGCGGAGGAGTGGCTGGCG
CGACCCCTGCCCGAGGGACTGCAGGCGTTCGGGGCCGTCCTCGTAGACGCCCATCGGCGC
ATCACCGACCCGGAGAGGGACATCCAGGACTTTGTCCTCACCGCCGAACTGAGCAGACAC
CCGCGCGCGTACACCAACAAGCGCCTGGCCCACCTGACGGTGTATTACAAGCTCATGGCC
CGCCGCGCGCAGGTCCCGTCCATCAAGGACCGGATCCCGTACGTGATCGTGGCCCAGACC
CGCGAGGTAGAGGAGACGGTCGCGCGGCTGGCCGCCCTCCGCGAGCTAGACGCCGCCGCC
CCAGGGGACGAGCCCGCCCCCCCCGCGGCCCTGCCCTCCCCGGCCAAGCGCCCCCGGGAG
ACGCCGTCGCCTGCCGACCCCCCGGGAGGCGCGTCCAAGCCCCGCAAGCTGCTGGTGTCC
GAGCTGGCCGAGGATCCCGCATACGCCATTGCCCACGGCGTCGCCCTGAACACGGACTAT
TACTTCTCCCACCTGTTGGGGGCGGCGTGCGTGACATTCAAGGCCCTGTTTGGGAATAAC
GCCAAGATCACCGAGAGTCTGTTAAAAAGGTTTATTCCCGAAGTGTGGCACCCCCCGGAC
GACGTGGCCGCGCGGCTCCGGACCGCAGGGTTCGGGGCGGTGGGTGCCGGCGCTACGGCG
GAGGAAACTCGTCGAATGTTGCATAGAGCCTTTGATACTCTAGCATGA
|
| Target 1 GenBank Gene ID |
|
| Target 1 GeneCard ID |
Not Available |
| Target 1 GenAtlas ID |
Not Available |
| Target 1 HGNC ID |
Not Available |
| Target 1 Chromosome Location |
Not Available |
| Target 1 Locus |
Not Available |
| Target 1 SNPs |
SNPJam Report  |
| Target 1 General References |
- McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, Perry LJ, Scott JE, Taylor P: The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988 Jul;69 ( Pt 7):1531-74. [PubMed
]
- Quinn JP, McGeoch DJ: DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein. Nucleic Acids Res. 1985 Nov 25;13(22):8143-63. [PubMed
]
|
| Target 1 Drug References |
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed
]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed
]
|
|
Drug Target 2
[top]
|
| Target 2 ID |
697 |
| Target 2 Name |
DNA polymerase |
| Target 2 Synonyms |
- EC 2.7.7.7
|
| Target 2 Gene Name |
28 |
| Target 2 Protein Sequence |
>DNA polymerase
MAIRTGFCNPFLTQASGIKYNPRTGRGSNREFLHSYKTTMSSFQFLAPKCLDEDVPMEER
KGVHVGTLSRPPKVYCNGKEVPILDFRCSSPWPRRVNIWGEIDFRGDKFDPRFNTFHVYD
IVETTEAASNGDVSRFATATRPLGTVITLLGMSRCGKRVAVHVYGICQYFYINKAEVDTA
CGIRSGSELSVLLAECLRSSMITQNDATLNGDKNAFHGTSFKSASPESFRVEVIERTDVY
YYDTQPCAFYRVYSPSSKFTNYLCDNFHPELKKYEGRVDATTRFLMDNPGFVSFGWYQLK
PGVDGERVRVRPASRQLTLSDVEIDCMSDNLQAIPNDDSWPDYKLLCFDIECKSGGSNEL
AFPDATHLEDLVIQISCLLYSIPRQSLEHILLFSLGSCDLPQRYVQEMKDAGLPEPTVLE
FDSEFELLIAFMTLVKQYAPEFATGYNIVNFDWAFIMEKLNSIYSLKLDGYGSINRGGLF
KIWDVGKSGFQRRSKVKINGLISLDMYAIATEKLKLSSYKLDSVAREALNESKRDLPYKD
IPGYYASGPNTRGIIGEYCIQDSALVGKLFFKYLPHLELSAVARLARITLTKAIYDGQQV
RIYTCLLGLASSRGFILPDGGYPATFEYKDVIPDVGDVEEEMDEDESVSPTGTSSGRNVG
YKGARVFDPDTGFYIDPVVVLDFASLYPSIIQAHNLCFTTLTLNFETVKRLNPSDYATFT
VGGKRLFFVRSNVRESLLGVLLKDWLAMRKAIRARIPGSSSDEAVLLDKQQAAIKVVCNS
VYGFTGVAQGFLPCLYVAATVTTIGRQMLLSTRDYIHNNWAAFERFITAFPDIESSVLSQ
KAYEVKVIYGDTDSVFIRFKGVSVEGIAKIGEKMAHIISTALFCPPIKLECEKTFIKLLL
ITKKKYIGVIYGGKVLMKGVDLVRKNNCQFINDYARKLVELLLYDDTVSRAAAEASCVSI
AEWNRRAMPSGMAGFGRIIADAHRQITSPKLDINKFVMTAELSRPPSAYINRRLAHLTVY
YKLVMRQGQIPNVRERIPYVIVAPTDEVEADAKSVALLRGDPLQNTAGKRCGEAKRKLII
SDLAEDPIHVTSHGLSLNIDYYFSHLIGTASVTFKALFGNDTKLTERLLKRFIPETRVVN
VKMLNRLQAAGFVCIHAPCWDNKMNTEAEITEEEQSHQIMRRVFCIPKAILHQS
|
| Target 2 Number of Residues |
1213 |
| Target 2 Molecular Weight |
134049 |
| Target 2 Theoretical pI |
7.94 |
| Target 2 GO Classification |
|
Function
|
hydrolase activity
hydrolase activity, acting on ester bonds
nuclease activity
exonuclease activity
3'-5' exonuclease activity
catalytic activity
transferase activity
transferase activity, transferring phosphorus-containing groups
nucleotidyltransferase activity
DNA-directed DNA polymerase activity
nucleic acid binding
DNA binding
binding
nucleotide binding |
|
Process
|
physiological process
metabolism
cellular metabolism
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
DNA metabolism
DNA replication |
|
Component
|
| Not Available |
|
| Target 2 General Function |
Replication, recombination and repair |
| Target 2 Specific Function |
Not Available |
| Target 2 Pathways |
|
| Target 2 Reactions |
- deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1
|
| Target 2 Pfam Domain Function |
|
| Target 2 Signals |
|
| Target 2 Transmembrane Regions |
|
| Target 2 Essentiality |
Essential |
| Target 2 GenBank ID Protein |
60016  |
| Target 2 UniProtKB/Swiss-Prot ID |
P09252  |
| Target 2 UniProtKB/Swiss-Prot Entry Name |
DPOL_VZVD  |
| Target 2 PDB ID |
Not Available |
| Target 2 Cellular Location |
|
| Target 2 Gene Sequence |
>3585 bp
TTAACTTTGATGGAGAATTGCTTTTGGAATACAAAAGACTCTACGCATTATTTGATGACT
TTGTTCCTCCTCGGTGATTTCAGCTTCAGTGTTCATTTTATTATCCCAGCACGGGGCGTG
TATACAAACAAAGCCTGCCGCCTGCAAGCGGTTTAGCATTTTAACGTTAACAACTCGTGT
CTCTGGAATAAAACGTTTTAAAAGCCGTTCTGTGAGTTTAGTGTCGTTTCCAAATAACGC
CTTAAAAGTTACACTCGCCGTCCCAATGAGATGAGAAAAATAATAGTCAATGTTTAAAGA
CAGCCCGTGTGATGTTACGTGAATGGGATCTTCCGCTAAGTCAGATATTATTAACTTACG
CTTTGCTTCCCCACACCGTTTACCTGCGGTATTCTGTAAAGGATCTCCACGTAGCAAAGC
TACACTTTTTGCATCAGCCTCCACTTCGTCTGTGGGGGCCACAATAACATAAGGGATGCG
TTCTCGAACGTTTGGGATTTGACCCTGTCTCATTACTAATTTATAATATACTGTTAAGTG
AGCCAAGCGACGGTTTATGTAGGCGGATGGTGGACGACTAAGCTCGGCCGTCATAACAAA
CTTATTAATATCCAATTTGGGTGATGTAATCTGGCGATGTGCATCTGCAATTATGCGTCC
AAACCCGGCCATCCCAGACGGCATGGCCCGTCTATTCCATTCAGCAATGGAAACACACGA
CGCCTCCGCCGCAGCACGCGAGACGGTGTCGTCATATAACAACAGTTCTACAAGTTTGCG
GGCATAATCGTTAATAAATTGACAGTTGTTTTTTCTAACCAAGTCGACTCCCTTCATTAA
AACCTTTCCGCCGTAAATTACCCCAATGTACTTTTTCTTTGTTATAAGCAAAAGTTTTAT
AAAAGTTTTTTCACACTCCAACTTTATAGGAGGACAAAACAGAGCCGTTGAAATTATATG
TGCCATTTTCTCGCCGATTTTAGCTATCCCCTCAACACTAACACCCTTGAATCGGATAAA
CACAGAATCCGTATCTCCATATATAACCTTTACCTCGTACGCTTTTTGGGAGAGAACGCT
ACTTTCAATGTCTGGAAACGCTGTAATAAAACGTTCAAATGCGGCCCAGTTATTATGAAT
ATAATCTCTGGTACTTAATAACATTTGACGGCCAATTGTAGTGACAGTGGCCGCTACGTA
TAAACATGGCAGAAATCCCTGCGCAACTCCAGTAAAACCGTACACGGAATTACAAACTAC
TTTTATCGCGGCTTGTTGTTTGTCTAATAACACTGCTTCATCTGAAGAACTTCCGGGTAT
GCGCGCTCTAATAGCCTTGCGCATAGCCAACCAGTCTTTTAAAAGAACACCCAGCAGACT
TTCTCGAACGTTAGAGCGCACAAAAAAAAGACGTTTTCCTCCAACTGTAAAGGTGGCATA
ATCGGATGGATTCAAACGTTTAACCGTCTCAAAATTTAACGTTAGCGTGGTAAAACATAA
GTTATGGGCCTGAATTATACTTGGATATAAACTTGCAAAATCCAATACGACCACCGGATC
GATATAAAATCCCGTATCAGGGTCAAAAACCCTGGCTCCTTTATATCCTACATTTCGCCC
ACTTGACGTACCAGTGGGAGAAACGCTCTCGTCTTCATCCATCTCTTCCTCAACATCCCC
GACATCGGGAATAACATCCTTATATTCAAAAGTAGCTGGGTATCCCCCATCGGGTAAAAT
AAATCCTCGAGACGAAGCCAGTCCTAATAAACAGGTGTAAATCCTAACCTGCTGTCCGTC
GTAAATAGCCTTGGTTAAAGTAATTCTAGCTAGCCTTGCAACCGCGGATAACTCAAGGTG
TGGTAAATATTTAAAAAACAGTTTCCCCACAAGAGCCGAGTCTTGTATACAATATTCACC
AATAATTCCTCGTGTATTCGGTCCACTAGCGTAATATCCCGGAATGTCTTTGTAGGGCAA
ATCTCTCTTGGACTCATTTAGAGCTTCACGTGCAACCGAATCTAATTTATAACTCGAGAG
TTTTAATTTTTCAGTTGCAATTGCATACATATCCAGAGATATGAGACCGTTGATCTTTAC
CTTGCTTCGTCGCTGAAATCCGGATTTGCCAACATCCCATATCTTAAACAGACCCCCACG
GTTTATACTGCCATAACCATCAAGCTTGAGACTGTATATAGAATTAAGTTTCTCCATAAT
AAACGCCCAATCAAAATTAACAATGTTATAACCTGTGGCAAACTCGGGAGCGTACTGTTT
TACGAGGGTCATAAATGCAATTAATAGCTCGAATTCACTATCAAACTCCAGCACAGTCGG
CTCCGGTAACCCCGCGTCCTTCATTTCTTGTACATACCTTTGTGGTAAGTCACAAGAGCC
AAGGGAAAACAGTAAAATGTGTTCTAAAGACTGTCGAGGGATTGAATATAATAGACAAGA
AATTTGGATTACAAGATCCTCCAGATGTGTTGCATCGGGAAACGCCAGCTCATTAGATCC
TCCTGATTTACATTCAATATCGAAACATAACAACTTGTAGTCAGGCCATGAGTCATCGTT
TGGTATAGCCTGCAGATTATCCGACATGCAGTCAATTTCAACGTCGCTTAACGTTAATTG
GCGACTTGCCGGTCGAACTCGAACACGTTCCCCATCAACTCCAGGTTTTAGTTGATACCA
ACCAAAACTAACAAAGCCGGGATTATCCATTAGAAAACGAGTGGTAGCGTCTACCCGACC
TTCATACTTTTTCAACTCCGGGTGAAAGTTATCACAAAGATAATTTGTAAATTTAGATGA
GGGAGAATACACCCTGTAAAACGCACATGGCTGTGTATCGTAGTAATAAACATCTGTGCG
CTCAATAACCTCAACGCGAAAGCTTTCTGGAGATGCGCTTTTAAACGAGGTACCATGAAA
AGCGTTCTTGTCTCCATTTAACGTTGCATCATTTTGTGTTATCATAGAACTGCGTAAACA
CTCGGCAAGTAATACAGATAACTCGCTACCGGAACGTATGCCACAAGCGGTATCCACCTC
GGCTTTGTTTATATAAAAATATTGACAGATGCCGTATACATGAACTGCCACCCTTTTTCC
ACATCGGGACATGCCAAGTAAAGTAATAACGGTACCAAGCGGTCGTGTTGCAGTTGCAAA
CCGGGATACATCTCCATTAGACGCGGCTTCTGTTGTTTCGACAATATCATATACATGGAA
TGTGTTAAAGCGGGGGTCAAACTTATCCCCACGAAAGTCGATTTCCCCCCAAATATTCAC
GCGTCTAGGCCAGGGGCTGGAACAACGAAAATCCAGAATCGGAACTTCTTTTCCATTACA
GTAAACTTTAGGCGGTCGACTAAGTGTACCGACGTGAACCCCCTTTCGTTCTTCCATGGG
CACATCTTCATCTAAACATTTAGGGGCCAAAAATTGAAACGATGACATGGTAGTTTTGTA
ACTATGAAGAAATTCTCTGTTACTACCGCGCCCGGTTCTTGGGTTATATTTAATCCCTGA
TGCTTGGGTTAAAAAGGGATTACAAAACCCCGTTCTGATCGCCAT
|
| Target 2 GenBank Gene ID |
|
| Target 2 GeneCard ID |
Not Available |
| Target 2 GenAtlas ID |
Not Available |
| Target 2 HGNC ID |
Not Available |
| Target 2 Chromosome Location |
Not Available |
| Target 2 Locus |
Not Available |
| Target 2 SNPs |
SNPJam Report  |
| Target 2 General References |
- Davison AJ, Scott JE: The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986 Sep;67 ( Pt 9):1759-816. [PubMed
]
|
| Target 2 Drug References |
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed
]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed
]
|